Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
04:02pm, Thursday, 15'th Feb 2024
MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Thursday, 08'th Feb 2024
MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 29'th Jan 2024
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
12:02pm, Tuesday, 09'th Jan 2024
Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
10:33am, Thursday, 04'th Jan 2024
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva
12:47pm, Tuesday, 02'nd Jan 2024
The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.
Corcept Therapeutics shares sink after losing patent infringement lawsuit against Teva
11:32am, Tuesday, 02'nd Jan 2024
Corcept Therapeutics shares fell by more than a quarter on Tuesday morning after a court found against it in a patent infringement lawsuit filed against Teva Pharmaceuticals. A US District Court said
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
11:17am, Friday, 08'th Dec 2023
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Corcept (CORT) Up 0.7% Since Last Earnings Report?
12:49pm, Friday, 01'st Dec 2023
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
10:01pm, Thursday, 09'th Nov 2023
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to
Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View
12:47pm, Thursday, 02'nd Nov 2023
Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023.
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Wednesday, 25'th Oct 2023
MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
10:32am, Monday, 18'th Sep 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade)
06:43am, Saturday, 26'th Aug 2023
Corcept Therapeutics' equity stock shows promising investment prospects with the resolution of its Korlym overhang and strong financial performance. The outcome of the trial against Teva Pharmaceutica
Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio
09:46am, Friday, 25'th Aug 2023
Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its promising set of pipeline candidates.
